anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Cabozantinib
Trial phase: Phase 1
ATC code: L01EX07 | L01XE26
SMILES: COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Dose level 0: cabozantinib 40 mg daily
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed prostate adenocarcinoma
Bone metastases confirmed by bone scan
Current androgen deprivation therapy
Castration-resistant disease based on progression in bone and/or PSA progression
Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, other non-clinically significant adverse events
Life expectancy of greater than 3 months
Normal organ and marrow function
Capable of understanding and complying with the protocol requirements
Agree to use medically accepted methods of contraception
Able to swallow capsules

Exclusion Criteria:

More than two prior chemotherapy regimens for metastatic prostate cancer
Known untreated, symptomatic or uncontrolled brain metastases
Serious or unhealed wound
Treatment with anticoagulants
Previously identified allergy or hypersensitivity to components of the study treatment formulation
History of a different malignancy unless disease-free for at least 5 years, or basal or squamous cell carcinoma of the skin
Current antiretroviral therapy
Uncontrolled hypertension
Uncontrolled intercurrent illness
Intervention: Cabozantinib
Trial phase: Phase 1
ATC code: L01EX07 | L01XE26
SMILES: COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Dose level -1: cabozantinib 20 mg daily
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed prostate adenocarcinoma
Bone metastases confirmed by bone scan
Current androgen deprivation therapy
Castration-resistant disease based on progression in bone and/or PSA progression
Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, other non-clinically significant adverse events
Life expectancy of greater than 3 months
Normal organ and marrow function
Capable of understanding and complying with the protocol requirements
Agree to use medically accepted methods of contraception
Able to swallow capsules

Exclusion Criteria:

More than two prior chemotherapy regimens for metastatic prostate cancer
Known untreated, symptomatic or uncontrolled brain metastases
Serious or unhealed wound
Treatment with anticoagulants
Previously identified allergy or hypersensitivity to components of the study treatment formulation
History of a different malignancy unless disease-free for at least 5 years, or basal or squamous cell carcinoma of the skin
Current antiretroviral therapy
Uncontrolled hypertension
Uncontrolled intercurrent illness
Intervention: Trazodone
Trial phase: Not Applicable
ATC code: N06AX05
SMILES: O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Trazodone: 50 mg once a day, for 3 months
Eligibility criteria:
Inclusion Criteria:

Chronic insomnia with duration of more than 1 year
Objective short sleep duration (< 6 hours)
BMI < 39
Ages 30-60
Men & Women

Exclusion Criteria:

Major Mental Illness
Substance Abuse/Dependence
Sleep Apnea
Periodic Limb Movement Disorder
Shift Work or circadian disorders
Diabetes
Chronic Renal Failure, Hepatic Insufficiency, Chronic Heart Failure
Current Use of hypnotics or sleep inducing sedative antidepressants
Intervention: Methylphenidate
Trial phase: Phase 2
ATC code: N06BA04 | N06BA11 | N06BA15
SMILES: COC(=O)C(c1ccccc1)C1CCCCN1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
Eligibility criteria:
INCLUSION CRITERIA:

Patient and family must agree to return to the clinic up to 8 times within 2 months
Children ≥ 8 and <18 years of age at the time of study entry who were previously treated for:
a hypothalamic tumor
mid-line brain tumor
a tumor involving one or both thalami
craniopharyngioma
diagnosis of hydrocephalus secondary to a brain tumor or treatment of a brain tumor that required placement of a permanent shunt.
Off cancer treatment for at least six months
Proficient in English
Able to swallow capsules
Experiencing symptoms of excessive daytime sleepiness (EDS) for at least three months prior to study entry that is not a result of inadequate sleep hygiene or other known medical disorder.
Negative pregnancy test

EXCLUSION CRITERIA:

Patients treated with doxorubicin or high dose cyclophosphamide
History of a clinically significant drug sensitivity to methylphenidate, modafinil, armodafinil or any of their components
Known cardiac disorders including arrhythmias, hypertension requiring treatment or structural heart disease
Have taken methylphenidate or modafinil within the last 14 days
Current/concurrent use of antihistamines, benzodiazepine, anticonvulsants or alcohol
Clinical diagnosis of major depression, subclinical depression, or anxiety disorder
History of psychosis or mania
Patients with suicidal ideation
Diagnosis with anemia, untreated hypothyroidism, mononucleosis or narcolepsy
History of substance abuse
Pregnant or breast feeding
A total dietary intake of more than 500 mg of caffeine per day (e.g., approximately ten 330 mL cans of soft drinks, five cups of coffee or tea, or 750 g chocolate per day).
Intervention: Hydrochlorothiazide
Trial phase: Phase 4
ATC code: C03AA03 | C03AB03 | C03AX01 | C03EA01 | C09BX03 | C09DX01 | C09DX03 | C09DX06 | C09DX07 | C09DX08 | C09XA52 | C09XA54 | G01AE10
SMILES: NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: aliskiren 300 mg daily
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes
prehypertension or Stage 1 hypertension

Exclusion Criteria:

Type 1 diabetes
Stage 2 hypertension
CKD
recent MI, revascularization, CVA or TIA
Intervention: Bupivacaine
Trial phase: Phase 1
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 14
Group description: Exparel: liposome bupivacaine
Eligibility criteria:
Inclusion Criteria:

greater than or equal to 18 years old
able and willing to have bilateral femoral nerve blocks placed and repeated motor/sensory testing for 24-120 hours (1-5 days), requiring 1-5 overnight stay(s) in the UCSD CTRI to allow dissipation of local anesthetic infusion effects to near-baseline values
have the ability to adequately communicate with all study personnel
willing and capable of providing written informed consent

Exclusion Criteria:

daily analgesic use for over one week within the past 6 months
opioid use within the previous 4 weeks
any neuro-muscular deficit of either femoral nerves and/or quadriceps muscles
body mass index > 30 kg/m2
current pregnancy
incarceration
any coagulation disorder
uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigators, may interfere with study assessments or adherence
any previous allergic reaction to fentanyl, midazolam, or an amide local anesthetic (bupivacaine is of the amide local anesthetic class)
any previous participation in a SKY0402/EXPAREL study
nursing mothers
suspected or known drug or alcohol abuse within the previous year; and/or
planning on becoming pregnant in the one month following study participation.
Intervention: Ranolazine
Trial phase: Phase 3
ATC code: C01EB18
SMILES: COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.

Ranolazine: Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
Eligibility criteria:
Inclusion Criteria:

Male or female with persistent atrial fibrillation, aged 21 or older
Duration of atrial fibrillation less than one year
The patient does not have any contraindications for anticoagulation
The patient is willing to participate in the study for a total of 6 months with 3 outpatient office visits
The patient has provided written informed consent during the screening visit to any test or procedure being performed, or medication being changed, for this study.
The patient has no clinically significant abnormal clinical laboratory values, which in the investigator's opinion precludes the patient from safely participating in the study.

Exclusion Criteria:

Any contraindication for anticoagulation
New York Heart Association class IV heart failure
Currently taking anti-arrhythmic drugs
Chronic kidney disease (serum creatinine less than 2.5mg/dL) or severe liver dysfunction
Pregnancy/nursing
Prolonged QT interval (>500ms)
Taking other medications known to prolong the QT interval
Taking other medications known to affect the metabolism of ranolazine
Intervention: Budesonide
Trial phase: Phase 3
ATC code: A07EA06 | D07AC09 | R01AD05 | R03AK07 | R03AK12 | R03AL11 | R03BA02
SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 114
Group description: Participants administered topical rectal budesonide foam at 2 mg/25 mL BID (morning and 12 hours later) for 2 weeks followed by 2 mg/25 mL QD (in the evenings) for 4 weeks for up to 8 cycles. After Cycle 1, participants needed to qualify to be able to participate in subsequent cycles. Participants underwent a 48-hour study drug washout period between each cycle.
Eligibility criteria:
Inclusion Criteria:

Male or non-pregnant, non-breast-feeding females ≥18 years old.
Participant was previously diagnosed with active mild to moderate UP/UPS and was currently experiencing symptoms of active UP/UPS disease after having completed participation in Salix's BUCF3001 (NCT01008410) or BUCF3002 (NCT01008423) study.
Willingness to undergo sigmoidoscopy.

Exclusion Criteria:

Active systemic, ocular, or cutaneous infection (for example, parasitic, fungal, amoebic, viral, or bacterial disease).
History of sclerosing cholangitis, cirrhosis, or hepatic impairment, including chronic hepatitis of any etiology.
Participant took systemic, inhaled, oral, topical, or rectal corticosteroids (other than budesonide rectal foam) within 7 days of starting a treatment cycle.
Participant took ketoconazole and other potent CYP3A4 inhibitors within 7 days of starting a treatment cycle.
Participant took diuretics with cardiac glycosides.
Unstable significant cardiovascular, hepatic, renal, endocrine, neurologic, or pulmonary disease.
Intervention: Ethanol
Trial phase: Phase 4
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: AmeriGel® wound care dressing alone

AmeriGel®: Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.

Hemoglobin A1c: Hemoglobin A1c levels will be performed and reviewed every three months to assess its relationship to wound healing
Eligibility criteria:
Inclusion Criteria:

>18 years of age
Diabetic (Type I and Type II)
Ulceration of the foot at least one centimeter in width/length
Ulceration at least 0.2 centimeters in depth

Exclusion Criteria:

Ulceration width/length > 7.5 centimeters
Wound depth > 1.25 centimeters
Purulent, excessive drainage and/or other signs of infection (i.e. erythema, edema, warmth)
Inability to provide informed consent
Inability to swallow pills (vitamin C supplement)
Patients with concurrent renal problems
Patients with medication contraindications to Vitamin C and/or topical wound dressings
Intervention: Ipratropium
Trial phase: Phase 2
ATC code: R01AX03 | R03AL01 | R03AL02 | R03BB01
SMILES: CC(C)[N+]1(C)C2CCC1CC(OC(=O)C(CO)c1ccccc1)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 48
Group description: Ipratropium Bromide HFA Inhalation Aerosol 34 µg QID.
Eligibility criteria:
Key Inclusion Criteria:

Signed written informed consent
40 - 80 years of age
Clinical history of COPD with airflow limitation that is not fully reversible
Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods
Current/former smokers with at least a 10 pack-year history of cigarette smoking
A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70
A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of predicted normal values
Able to change COPD treatment as required by protocol

Key Exclusion Criteria:

Women who are pregnant or lactating
Primary diagnosis of asthma
Alpha-1 antitrypsin deficiency as the cause of COPD
Active pulmonary diseases
Prior lung volume reduction surgery
Abnormal chest X-ray (or CT scan) not due to the presence of COPD
Hospitalized due to poorly controlled COPD within 3 months of Screening
Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)
Cancer that has not been in complete remission for at least 5 years
Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives

Other inclusion/exclusion criteria as defined in the protocol
Intervention: Mebendazole
Trial phase: Phase 3
ATC code: P02CA01 | P02CA51
SMILES: COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 214
Group description: Hookworm positive participants randomized to a single dose of Mebendazole polymorph A and C 500 mg
Eligibility criteria:
Inclusion Criteria:

Necator americanus infection, as determined by examination of a single faecal smear, alone or with Ascaris lumbricoides or Trichuris trichiura

Exclusion Criteria:

Children below the age of 2 years
Pregnant women
Individuals with diarrhea on day of treatment
Intervention: Mebendazole
Trial phase: Phase 3
ATC code: P02CA01 | P02CA51
SMILES: COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 214
Group description: Hookworm positive participants randomized to a single dose of Mebendazole polymorph C 500 mg
Eligibility criteria:
Inclusion Criteria:

Necator americanus infection, as determined by examination of a single faecal smear, alone or with Ascaris lumbricoides or Trichuris trichiura

Exclusion Criteria:

Children below the age of 2 years
Pregnant women
Individuals with diarrhea on day of treatment
Intervention: Febuxostat
Trial phase: Not Applicable
ATC code: M04AA03
SMILES: Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Febuxostat: 80 mg/day of febuxostat for 24 weeks
Eligibility criteria:
Inclusion Criteria:

Age > 18 years
BMI > 25 kg/m2
type 2 diabetes
serum uric acid ≥ 5.5 mg/dl in men and ≥ 4.6 mg/dl in women
eGFR 30-60 mL/min/1.73m2

Exclusion Criteria:

History of gout
concurrent use of azathioprine, mercaptopurine, theophylline, allopurinol, thiazolidinediones or warfarin
concurrent use of metformin
current antibiotic therapy
pregnant women
prisoners
Intervention: Lovaza
Trial phase: Phase 3
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 205
Group description: TAK-085 2 g, orally, once daily for up to 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Participants with values of fasting triglyceride level at Visit 2 (Week -4) and Visit 3 (Week -2) are 150 mg/dL or higher and less than 750 mg/dL, and the difference between these 2 values is within 30% of the higher one.
Participants with differences between 2 values of fasting Low density lipoprotein - cholesterol level measured at Visit 2 (Week -4) and Visit 3 (Week -2) are within 25% of the higher one.

Exclusion Criteria:

Participants who have coronary artery diseases (eg, confirmed myocardial infarction and angina pectoris) within 6 months prior to Visit 1 (Week -8) or participants with a history of revascularization.
Participants who received aortic aneurysmectomy or is complicated with aortic aneurysm within 6 months prior to Visit 1 (Week -8).
Participants who have a history or complication of a clinically significant hemorrhagic disease (eg, hemophilia, capillary fragility illness, digestive tract ulcer, urinary tract hemorrhage, hemoptysis, vitreous haemorrhage and so forth) within 6 months prior to Visit 1 (Week -8).
Participants who have been diagnosed with pancreatitis.
Participants who have been diagnosed with lipoprotein lipase (LPL) deficiency, apolipoprotein C-II deficiency or type III familial hyperlipidemia.
Participants with complication of Cushing's syndrome, uremia, systemic lupus erythematosus (SLE) or serum dysproteinemia.
Intervention: Lovaza
Trial phase: Phase 3
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 210
Group description: TAK-085 2 g, orally, twice daily for up to 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Participants with values of fasting triglyceride level at Visit 2 (Week -4) and Visit 3 (Week -2) are 150 mg/dL or higher and less than 750 mg/dL, and the difference between these 2 values is within 30% of the higher one.
Participants with differences between 2 values of fasting Low density lipoprotein - cholesterol level measured at Visit 2 (Week -4) and Visit 3 (Week -2) are within 25% of the higher one.

Exclusion Criteria:

Participants who have coronary artery diseases (eg, confirmed myocardial infarction and angina pectoris) within 6 months prior to Visit 1 (Week -8) or participants with a history of revascularization.
Participants who received aortic aneurysmectomy or is complicated with aortic aneurysm within 6 months prior to Visit 1 (Week -8).
Participants who have a history or complication of a clinically significant hemorrhagic disease (eg, hemophilia, capillary fragility illness, digestive tract ulcer, urinary tract hemorrhage, hemoptysis, vitreous haemorrhage and so forth) within 6 months prior to Visit 1 (Week -8).
Participants who have been diagnosed with pancreatitis.
Participants who have been diagnosed with lipoprotein lipase (LPL) deficiency, apolipoprotein C-II deficiency or type III familial hyperlipidemia.
Participants with complication of Cushing's syndrome, uremia, systemic lupus erythematosus (SLE) or serum dysproteinemia.
Intervention: Atazanavir
Trial phase: Phase 4
ATC code: J05AE08 | J05AR15 | J05AR23
SMILES: COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Switch to atazanavir 400 mg daily
Eligibility criteria:
Inclusion Criteria:

HIV infected adults at least 19 years of age
Willing and able to provide informed consent to study participation
Currently receiving a regimen including atazanavir 300mg/ritonavir 100mg daily with either tenofovir/emtricitabine (FTC) or tenofovir/lamivudine (3TC), for at least 3 months
Plasma viral load (VL) <40 copies/mL for at least 2 consecutive measurements including the screening value, and < 150 copies/mL continuously for at least 3 months prior to screening
Current regimen is first antiretroviral regimen, or if not first regimen, no evidence of resistance to any nucleosides (NRTIs) or protease inhibitors (PIs) on previous resistance tests
Any CD4

Exclusion Criteria:

Clinically significant intolerance or toxicity with current regimen precluding regimen continuation (e.g. intolerance/toxicity to ritonavir necessitating ritonavir discontinuation)
pregnancy or breast-feeding
antiretroviral regimen including any nonnucleoside reverse transcriptase inhibitor (nevirapine, efavirenz, or etravirine)
antiretroviral regimen including any protease inhibitor other than atazanavir and ritonavir
concomitant treatment with proton pump inhibitors, rifampin, St. John's wort, or garlic supplements. (Antacids and H2 receptor antagonists will be allowed provided their dosing is separated from atazanavir administration by at least 2 and 10 hours, respectively).
Intervention: Nicotine
Trial phase: Phase 3
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 39
Group description: Eight, 60-minute group sessions over an 8 week period
Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking, and will continue after treatment sessions have ended
Eligibility criteria:
Inclusion Criteria:

between 18 and 21 years of age
a regular smoker for at least 6 months
currently smoking an average of at least 5 cigarettes per day
want to quit smoking
report current elevated depressive symptoms

Exclusion Criteria:

current Axis I disorder
psychoactive substance dependence (excluding nicotine dependence) within the past 6 months
current use of psychotropic medication or participation in any form of psychotherapy
a history of significant medical condition (e.g., cardiovascular , neurological, gastrointestinal), pregnancy and/or breast feeding, or other systemic illness
limited mental competency [Mini Mental State Examination score < 23] and/or the inability to give informed, voluntary, written consent to participate
current use of any pharmacotherapy for smoking cessation not provided by the researchers during the quit attempt

Additional Exclusion criteria only for the fMRI portion:

cerebrovascular disease
high blood pressure
diabetes
use of psychotropic medications in 3 weeks prior to participation in fMRI protocol
exposure to extreme trauma
lifetime history of mania, psychosis, or pervasive developmental disorder,
being ambidextrous or left handed
any metal implants, heart pacemaker, permanent retainer
tattoos containing metal dyes
claustrophobia.
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 89
Group description: esomeprazole (40 mg/day) plus aspirin (100 mg/day) for 8 weeks

aspirin: aspirin, 100 mg, qd x 8 weeks
Eligibility criteria:
Inclusion Criteria:

aspirin users who have a peptic ulcer confirmed by endoscopy

Exclusion Criteria:

serious medical illness (including cardiovascular events within 6 months before endoscopy)
acute gastrointestinal bleeding
a history of gastric or duodenal surgery
allergic to the study drugs
require long-term treatment with non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, or anticoagulant agents
pregnancy